Poor Long-Term Survival in Patients With Moderate Aortic Stenosis.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
15 10 2019
Historique:
received: 25 06 2019
revised: 25 07 2019
accepted: 05 08 2019
pubmed: 7 9 2019
medline: 2 6 2020
entrez: 7 9 2019
Statut: ppublish

Résumé

Historical data suggesting poor survival in patients with aortic stenosis (AS) who do not undergo treatment are largely confined to patients with severe AS. This study sought to determine the prognostic impact of all levels of native valvular AS. Severity of AS was characterized by convention and by statistical distribution in 122,809 male patients (mean age 61 ± 17 years) and 118,494 female patients (mean age 62 ± 19 years), with measured aortic valve (AV) mean gradient, peak velocity, and/or area. The relationship between AS severity and survival was then examined during median 1,208 days (interquartile range: 598 to 2,177 days) of follow-up. Patients with previous aortic valve intervention were excluded. Overall, 16,129 (6.7%), 3,315 (1.4%), and 6,383 (2.6%) patients had mild, moderate, and severe AS, respectively. On an adjusted basis (vs. no AS; 5-year mortality 19%), patients with mild to severe AS had an increasing risk of long-term mortality (adjusted hazard ratio: 1.44 to 2.09; p < 0.001 for all comparisons). The 5-year mortality was 56% and 67%, respectively, in those with moderate AS (mean gradient 20.0 to 39.0 mm Hg/peak velocity 3.0 to 3.9 m/s) and severe AS (≥40.0 mm Hg, ≥4.0 m/s, or AV area <1.0 cm These data confirm that when left untreated, severe AS is associated with poor long-term survival. Moreover, they also suggest poor survival rates in patients with moderate AS. (National Echocardiographic Database of Australia [NEDA]; ACTRN12617001387314).

Sections du résumé

BACKGROUND
Historical data suggesting poor survival in patients with aortic stenosis (AS) who do not undergo treatment are largely confined to patients with severe AS.
OBJECTIVES
This study sought to determine the prognostic impact of all levels of native valvular AS.
METHODS
Severity of AS was characterized by convention and by statistical distribution in 122,809 male patients (mean age 61 ± 17 years) and 118,494 female patients (mean age 62 ± 19 years), with measured aortic valve (AV) mean gradient, peak velocity, and/or area. The relationship between AS severity and survival was then examined during median 1,208 days (interquartile range: 598 to 2,177 days) of follow-up. Patients with previous aortic valve intervention were excluded.
RESULTS
Overall, 16,129 (6.7%), 3,315 (1.4%), and 6,383 (2.6%) patients had mild, moderate, and severe AS, respectively. On an adjusted basis (vs. no AS; 5-year mortality 19%), patients with mild to severe AS had an increasing risk of long-term mortality (adjusted hazard ratio: 1.44 to 2.09; p < 0.001 for all comparisons). The 5-year mortality was 56% and 67%, respectively, in those with moderate AS (mean gradient 20.0 to 39.0 mm Hg/peak velocity 3.0 to 3.9 m/s) and severe AS (≥40.0 mm Hg, ≥4.0 m/s, or AV area <1.0 cm
CONCLUSIONS
These data confirm that when left untreated, severe AS is associated with poor long-term survival. Moreover, they also suggest poor survival rates in patients with moderate AS. (National Echocardiographic Database of Australia [NEDA]; ACTRN12617001387314).

Identifiants

pubmed: 31491546
pii: S0735-1097(19)36192-3
doi: 10.1016/j.jacc.2019.08.004
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1851-1863

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. All rights reserved.

Auteurs

Geoff Strange (G)

School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia. Electronic address: gstrange@neda.net.au.

Simon Stewart (S)

Torrens University Australia, Adelaide, South Australia, Australia.

David Celermajer (D)

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

David Prior (D)

University of Melbourne, St. Vincent's Hospital, Melbourne, Victoria, Australia.

Gregory M Scalia (GM)

University of Queensland, The Prince Charles Hospital, Brisbane, Queensland, Australia.

Thomas Marwick (T)

Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Marcus Ilton (M)

Menzies School of Health Research, Royal Darwin Hospital, Darwin, Northern Territory, Australia.

Majo Joseph (M)

Flinders University, Adelaide, South Australia, Australia.

Jim Codde (J)

University of Notre Dame, Fremantle, Western Australia, Australia.

David Playford (D)

School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH